Recommended for investigation of: 1) a patient with suspected or proven thymoma, whether or not symptoms or signs of MG are present (also of value for serially monitoring patients after removal of thymoma; a rising autoantibody titer may herald tumor persistence or recurrence), or emergence of an unrelated neoplasm and 2) a bone marrow transplant recipient with suspected graft-vs.-host disease, particularly if there is evidence of weakness.
Muscle AChR Binding Ab: <=0.02 nmol/L; Muscle AChR Modulating Ab: 0 - 20%; Striational Ab: <1:120; CRMP-5-IgG Western Blot: Negative; AChR Ganglionic Neuronal Ab: <=0.02 nmol/L; Glutamic Acid Decarboxylase Ab: <=0.02 nmol/L; Voltage-Gated Potassium Channel Ab: <=0.02 nmol/L.
* Reference ranges may change over time. Please refer to the original patient report when evaluating results.
3 - 7 days
- ACh Receptor (Muscle) Binding Antibody
- ACh Receptor (Muscle) Modulating Antibody
- AChR Ganglionic Neuronal Antibody
- CRMP-5 IgG
- Striational (Striated Muscle) Antibody
- AChR Antibodies
- Acetylcholine Receptor Antibodies
- GAD65 Antibody
- Neuronal (V-G) K Channel Antibody
Evaluation includes the following tests: AChR Binding Ab, AChR Modulating Ab, Striational Ab, AChR Ganglionic Neuronal Ab, CRMP-5-IgG Western Blot, Glutamic Acid Decarboxylase Ab (GAD65), and Voltage-Gated Potassium Channel Ab. Test sent to Mayo Medical Laboratories.